WHO: Jim O'Shea, CEO, & John Gandolfo, CFO
Bioject Medical Technologies (Nasdaq: BJCT)
WHEN: February 27, 2002
WHERE: http://www.bioject.com (Investor Relations Page)
WHAT: Webcast replay of investor conference call updating
announcement that Amgen elects not to pursue further
development of drugs along with Bioject's needle-free delivery
systems.
Yesterday, Tuesday, February 26, 2002, Amgen Inc. gave notice
to Bioject of its election not to pursue further development of
the drugs it was developing for distribution along with
Bioject's needle-free drug delivery systems. Amgen cited
internal business reasons for its decision to halt development
efforts. The company has not terminated its agreements with
Bioject and still holds options to further license the
needle-free technologies for certain other undisclosed
indications.
Jim O'Shea, CEO and John Gandolfo, CFO held a conference call to provide
further details regarding the impact on Bioject's sales, forecasts, and future
plans for the year.
A re-broadcast of the conference call is available immediately.
CONTACT: Cecelia Heer of Bioject Medical Technologies, Inc.,
+1-973-605-8554, or cheer@bioject.com.
SOURCE Bioject Medical Technologies, Inc.
back to top
